Skip to content

Absci Corp

US · ABSI #2817 by market cap Listed 2021
7.51 -0.65 -7.97%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Valuation each multiple against its own 5-year range

P/B ratio 6.67 Expensive vs history 95th percentile
5-year average 2.26 · #422 of 514 in Biotechnology
P/E ratio -10.70 Cheap vs history 6th percentile
5-year average -3.87 · forward -11.13
P/S ratio 981.64 Expensive vs history 95th percentile
5-year average 171.91 · forward 463.40 · #351 of 389 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Absci Corp (ABSI) 1.30B -9.51 5.93 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★★☆ Fair value16.64 Economic moatNone UncertaintyVery High

Trading 121.5% below Morningstar's fair value estimate.

Fair value

Absci Corp receives a 4-star quantitative star rating, reflecting our opinion that this share class offers a somewhat attractive opportunity for investors. The stock currently trades at a 49% discount to our quantitative fair value estimate of $16.64 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

The firm's liquidity strengthens our fair value estimate. Adequate liquidity allows a company to meet short-term obligations, enhancing financial stability and reducing distress risk. For example, the firm's median trading volume over the past 60 days lies in the top 20% compared with global peers. Trading volumes are high on shares, which may indicate increased institutional interest in stock ownership. We believe this is a sign that shares could be cheap.

Alternatively, the firm's valuation metrics are potentially concerning. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's enterprise value to revenue ratio, a core component of valuation, sits in the top 1% compared with global peers. This overstates the long-term cash flow growth potential of the organization. Despite our favorable price/fair value ratio, this characteristic is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance bodes well for future returns in light of other contributors to our model.

Economic moat

With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 20:02:23 · For reference only, not investment advice and not tailored to your situation.

Absci Corp discussion 0 comments

Add a comment